Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A for flexed knee gait in cerebral palsy
NCT00261131Phase 3Completed
- Sponsor
- Shriners Children's
- Start
- Mar 2006
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in spastic diplegic cerebral palsy (SDCP), sponsored by Shriners Children's. Primary endpoint: 3D Gait Analysis Kinematics at 24 weeks. Started Mar 2006; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
spastic diplegic cerebral palsy (SDCP)
Beyond the preview
Go deeper on NCT00261131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261131.